Document is current
Any future updates will be listed below
-
Authors
Dettling, Angela
Weimann, Jessica
Sundermeyer, Jonas
Beer, Benedikt N.
Besch, Lisa
Becher, Peter M.
Brunner, Fabian J.
Kluge, Stefan
Kirchhof, Paulus
Blankenberg, Stefan
Westermann, Dirk
Schrage, Benedikt https://orcid.org/0000-0001-9041-3922
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 3 August 2023
Accepted: 27 October 2023
First Online: 20 November 2023
Declarations
:
: BS received speaker fees from Abiomed, AstraZeneca and Abbott; and research support from Abiomed, the German Research Foundation and the Else Kröner-Fresenius-Stiftung. PK was partially supported by European Union AFFECT-AF (grant agreement 847770), and MAESTRIA (grant agreement 965286), British Heart Foundation (PG/17/30/32961; PG/20/22/35093; AA/18/2/34218), German Centre for Cardiovascular Research supported by the German Ministry of Education and Research (DZHK), Deutsche Forschungsgemeinschaft (Ki 509167694), and Leducq Foundation. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). FJB reports grants from Daiichi Sankyo, Novartis, Pfizer, and Sanofi, non-financial support from Abbott, ASAHI INTECC, and Inari Medical, personal fees from Amgen and Novartis outside of the submitted work. The other authors have no conflicts of interest to declare.
